Table 2.
Summary of the demographic and clinical features of the patients
| Group 1 (Patients with exon 2 mutations) n:82 |
Group 2 (Patients with exon 10 mutations) n:1304 |
Group 3 (Patients with exon 2 and 10 mutations) n:140 |
p | Bonferroni’s correction (post hoc test) | |
|---|---|---|---|---|---|
| Sex [M n (%)] | 28 (34.1) | 630 (48.3) | 80 (57.1) | 0.001 | 1–2: p=0.016 1–3: p=0.012 2–3: p=0.05 |
| Age at baseline clinical visit [Median (%25–%75)] | 26.5 (19.75–37) | 24 (18–34) | 27.5 (21.25–37.75) | 0.114 | |
| Age at onset of symptoms [Median (%25–%75)] | 20 (13–26) | 14 (8–21) | 19 (13–25) | <0.001 | 2–3: <0.001 2–1: <0.001 1–3: 0.931 |
| Fever | 71 (86.6) | 1196 (91.7) | 128 (91.4) | 0.274 | |
| Peritonitis | 78 (95.1) | 1232 (94.5) | 131 (93.6) | 0.871 | |
| Pleuritis | 37 (45.1) | 653 (50.1) | 68 (48.6) | 0.660 | |
| ELE* | 3 (3.7) | 351 (26.9) | 24 (17.1) | <0.001 | 1–2: <0.001 1–3: 0.003 2–3: 0.01 |
| Arthritis | 22 (26.8) | 594 (45.6) | 45 (32.1) | <0.0001 | 1–2: 0.01 1–3: 0.45 2–3: 0.002 |
| Myalgia | 12 (14.6) | 199 (15.3) | 19 (13.6) | 0.863 | |
| Vasculitis | 2 (2.4) | 100 (7.7) | 5 (3.6) | 0.490 | |
| Amyloidosis | 3 (3.7) | 133 (10.2) | 6 (4.3) | 0.014 | 1–2: 0.02 1–3: 1 2–3: 0.05 |
| CRF** | 1 (1.2) | 69 (5.3) | 3 (2.1) | 0.75 | |
| Family history of FMF | 32 (39) | 780 (59.8) | 73 (52.1) | <0.001 | 1–2: <0.001 1–3: 0.07 2–3: 0.08 |
| Family history of amyloidosis | 5 (6.1) | 267 (20.5) | 25 (17.9) | 0.005 | 1–2: 0.01 1–3: 0.01 2–3: 0.51 |
| Family history of CRF | 3 (3.7) | 79 (6.1) | 7 (5) | 0.606 |
Data are given as n (%);
*
ELE: erysipel-like erythema;
**
CRF: chronic renal failure